Clinical Trials · NCT04012255
A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity
- Phase
- Phase 1
- Recruitment status
- Terminated
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 29
- Start date
- Jul 2019
- Locations
- 2 sites, Germany
- Primary endpoint
- AUC0-168h,2.4mg,SS: Area under the semaglutide concentration time curve following the last administration of semaglutide s.c. 2.4 mg